Publication

Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment

Dobrolińska, M., van der Tuuk, K., Vink, P., van den Berg, M., Schuringa, A., Monroy-Gonzalez, A. G., Vállez García, D., Schultz, W. C. M. W. & Slart, R. H. J. A., Sep-2019, In : Journal of Sexual Medicine. 16, 9, p. 1469-1477 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Dobrolińska, M., van der Tuuk, K., Vink, P., van den Berg, M., Schuringa, A., Monroy-Gonzalez, A. G., ... Slart, R. H. J. A. (2019). Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. Journal of Sexual Medicine, 16(9), 1469-1477. https://doi.org/10.1016/j.jsxm.2019.06.006

Author

Dobrolińska, Magdalena ; van der Tuuk, Karin ; Vink, Patti ; van den Berg, Marjan ; Schuringa, Anke ; Monroy-Gonzalez, Andrea G. ; Vállez García, David ; Schultz, Willibrord C.M.Weijmar ; Slart, Riemer H.J.A. / Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. In: Journal of Sexual Medicine. 2019 ; Vol. 16, No. 9. pp. 1469-1477.

Harvard

Dobrolińska, M, van der Tuuk, K, Vink, P, van den Berg, M, Schuringa, A, Monroy-Gonzalez, AG, Vállez García, D, Schultz, WCMW & Slart, RHJA 2019, 'Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment', Journal of Sexual Medicine, vol. 16, no. 9, pp. 1469-1477. https://doi.org/10.1016/j.jsxm.2019.06.006

Standard

Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. / Dobrolińska, Magdalena; van der Tuuk, Karin; Vink, Patti; van den Berg, Marjan; Schuringa, Anke; Monroy-Gonzalez, Andrea G.; Vállez García, David; Schultz, Willibrord C.M.Weijmar; Slart, Riemer H.J.A.

In: Journal of Sexual Medicine, Vol. 16, No. 9, 09.2019, p. 1469-1477.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Dobrolińska M, van der Tuuk K, Vink P, van den Berg M, Schuringa A, Monroy-Gonzalez AG et al. Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. Journal of Sexual Medicine. 2019 Sep;16(9):1469-1477. https://doi.org/10.1016/j.jsxm.2019.06.006


BibTeX

@article{a5123e5eb4214858aebd1d49be74c91d,
title = "Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment",
abstract = "Introduction: Establishing the influence of long-term, gender-affirming hormonal treatment (HT) on bone mineral density (BMD) in transgender individuals is important to improve the therapeutic guidelines for these individuals. Aim: To examine the effect of long-term HT and gonadectomy on BMD in transgender individuals. Methods: 68 transwomen and 43 transmen treated with HT who had undergone gonadectomy participated in this study. Dual-energy x-ray absorptiometry (DXA) scans were performed to measure BMD at the lumbar spine and total hip. Laboratory values related to sex hormones were collected within 3 months of performing the DXA scan and analyzed. Main Outcome Measure: BMD and levels of sex hormones in transwomen and transmen. Results: In transwomen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 0.99 ± 0.15 g/cm2 (n = 68) and 0.94 ± 0.28 g/cm2 (n = 65). In transmen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 1.08 ± 0.16 g/cm2 (n = 43) and 1.01 ± 0.18 g/cm2 (n = 43). A significant decrease in total hip BMD was found in both transwomen and transmen after 15 years of HT compared with 10 years of HT (P =.02). Conclusion: In both transwomen and transmen, a decrease was observed in total hip bone mineral density after 15 years of HT compared to the first 10 years of HT. Dobrolińska M, van der Tuuk K, Vink P, et al. Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. J Sex Med 2019; 16:1469–1477.",
keywords = "Cross-sex hormonal treatment, Gender dysphoria, Transgender",
author = "Magdalena Dobrolińska and {van der Tuuk}, Karin and Patti Vink and {van den Berg}, Marjan and Anke Schuringa and Monroy-Gonzalez, {Andrea G.} and {V{\'a}llez Garc{\'i}a}, David and Schultz, {Willibrord C.M.Weijmar} and Slart, {Riemer H.J.A.}",
year = "2019",
month = "9",
doi = "10.1016/j.jsxm.2019.06.006",
language = "English",
volume = "16",
pages = "1469--1477",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "ELSEVIER SCI LTD",
number = "9",

}

RIS

TY - JOUR

T1 - Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment

AU - Dobrolińska, Magdalena

AU - van der Tuuk, Karin

AU - Vink, Patti

AU - van den Berg, Marjan

AU - Schuringa, Anke

AU - Monroy-Gonzalez, Andrea G.

AU - Vállez García, David

AU - Schultz, Willibrord C.M.Weijmar

AU - Slart, Riemer H.J.A.

PY - 2019/9

Y1 - 2019/9

N2 - Introduction: Establishing the influence of long-term, gender-affirming hormonal treatment (HT) on bone mineral density (BMD) in transgender individuals is important to improve the therapeutic guidelines for these individuals. Aim: To examine the effect of long-term HT and gonadectomy on BMD in transgender individuals. Methods: 68 transwomen and 43 transmen treated with HT who had undergone gonadectomy participated in this study. Dual-energy x-ray absorptiometry (DXA) scans were performed to measure BMD at the lumbar spine and total hip. Laboratory values related to sex hormones were collected within 3 months of performing the DXA scan and analyzed. Main Outcome Measure: BMD and levels of sex hormones in transwomen and transmen. Results: In transwomen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 0.99 ± 0.15 g/cm2 (n = 68) and 0.94 ± 0.28 g/cm2 (n = 65). In transmen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 1.08 ± 0.16 g/cm2 (n = 43) and 1.01 ± 0.18 g/cm2 (n = 43). A significant decrease in total hip BMD was found in both transwomen and transmen after 15 years of HT compared with 10 years of HT (P =.02). Conclusion: In both transwomen and transmen, a decrease was observed in total hip bone mineral density after 15 years of HT compared to the first 10 years of HT. Dobrolińska M, van der Tuuk K, Vink P, et al. Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. J Sex Med 2019; 16:1469–1477.

AB - Introduction: Establishing the influence of long-term, gender-affirming hormonal treatment (HT) on bone mineral density (BMD) in transgender individuals is important to improve the therapeutic guidelines for these individuals. Aim: To examine the effect of long-term HT and gonadectomy on BMD in transgender individuals. Methods: 68 transwomen and 43 transmen treated with HT who had undergone gonadectomy participated in this study. Dual-energy x-ray absorptiometry (DXA) scans were performed to measure BMD at the lumbar spine and total hip. Laboratory values related to sex hormones were collected within 3 months of performing the DXA scan and analyzed. Main Outcome Measure: BMD and levels of sex hormones in transwomen and transmen. Results: In transwomen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 0.99 ± 0.15 g/cm2 (n = 68) and 0.94 ± 0.28 g/cm2 (n = 65). In transmen, the mean BMD values at the lumbar spine and total hip at the first DXA scan were, respectively, 1.08 ± 0.16 g/cm2 (n = 43) and 1.01 ± 0.18 g/cm2 (n = 43). A significant decrease in total hip BMD was found in both transwomen and transmen after 15 years of HT compared with 10 years of HT (P =.02). Conclusion: In both transwomen and transmen, a decrease was observed in total hip bone mineral density after 15 years of HT compared to the first 10 years of HT. Dobrolińska M, van der Tuuk K, Vink P, et al. Bone Mineral Density in Transgender Individuals After Gonadectomy and Long-Term Gender-Affirming Hormonal Treatment. J Sex Med 2019; 16:1469–1477.

KW - Cross-sex hormonal treatment

KW - Gender dysphoria

KW - Transgender

U2 - 10.1016/j.jsxm.2019.06.006

DO - 10.1016/j.jsxm.2019.06.006

M3 - Article

VL - 16

SP - 1469

EP - 1477

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 9

ER -

ID: 95426952